Yu He (Arthur)'s questions to Aurinia Pharmaceuticals Inc (AUPH) leadership • Q2 2025
Question
Yu He asked if Aurinia plans to present detailed data from the Aratinircept single ascending dose study at a medical conference and under what circumstances the company would disclose the specific indications it is pursuing for the drug.
Answer
Chief Medical Officer Dr. Greg Keenan confirmed the data will be presented at a future, yet-to-be-determined medical meeting. President and CEO Peter Greenleaf explained that indication details are being withheld for competitive reasons, with the earliest public disclosure likely occurring when the trials are registered on clinicaltrials.gov.